1. Home
  2. RVPHW vs CLMT Comparison

RVPHW vs CLMT Comparison

Compare RVPHW & CLMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPHW
  • CLMT
  • Stock Information
  • Founded
  • RVPHW N/A
  • CLMT 1916
  • Country
  • RVPHW United States
  • CLMT United States
  • Employees
  • RVPHW 15
  • CLMT N/A
  • Industry
  • RVPHW Biotechnology: Pharmaceutical Preparations
  • CLMT Oil & Gas Production
  • Sector
  • RVPHW Health Care
  • CLMT Energy
  • Exchange
  • RVPHW Nasdaq
  • CLMT Nasdaq
  • Market Cap
  • RVPHW N/A
  • CLMT N/A
  • IPO Year
  • RVPHW 2018
  • CLMT 2006
  • Fundamental
  • Price
  • RVPHW $0.17
  • CLMT $18.40
  • Analyst Decision
  • RVPHW
  • CLMT Strong Buy
  • Analyst Count
  • RVPHW 0
  • CLMT 4
  • Target Price
  • RVPHW N/A
  • CLMT $25.75
  • AVG Volume (30 Days)
  • RVPHW N/A
  • CLMT 1.1M
  • Earning Date
  • RVPHW N/A
  • CLMT 02-21-2025
  • Dividend Yield
  • RVPHW N/A
  • CLMT N/A
  • EPS Growth
  • RVPHW N/A
  • CLMT N/A
  • EPS
  • RVPHW N/A
  • CLMT N/A
  • Revenue
  • RVPHW N/A
  • CLMT $4,216,399,999.00
  • Revenue This Year
  • RVPHW N/A
  • CLMT N/A
  • Revenue Next Year
  • RVPHW N/A
  • CLMT N/A
  • P/E Ratio
  • RVPHW N/A
  • CLMT N/A
  • Revenue Growth
  • RVPHW N/A
  • CLMT 0.30
  • 52 Week Low
  • RVPHW N/A
  • CLMT $9.97
  • 52 Week High
  • RVPHW N/A
  • CLMT $25.29
  • Technical
  • Relative Strength Index (RSI)
  • RVPHW N/A
  • CLMT 36.29
  • Support Level
  • RVPHW N/A
  • CLMT $20.61
  • Resistance Level
  • RVPHW N/A
  • CLMT $23.20
  • Average True Range (ATR)
  • RVPHW 0.00
  • CLMT 1.38
  • MACD
  • RVPHW 0.00
  • CLMT -0.40
  • Stochastic Oscillator
  • RVPHW 0.00
  • CLMT 19.67

About RVPHW Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: